

**MINUTE
AREA DRUG AND THERAPEUTICS COMMITTEE
WEDNESDAY 17th November @10am
Microsoft Teams Meeting**

In Attendance:

Dr Mehrdad Malekian	Mrs Karen Patterson	Mr John Milne
Dr Stephanie Dundas	Mrs Carol McGoff	Mrs Penny Brankin
Mrs Katrina Maroni	Mrs Emma Harris	Dr Iain Hathorn
Mrs Gail Richardson	Mr George Lindsay	Dr Tyra Smyth

Action

1.	<u>Apologies for Absence</u> Dr David Semple, Mrs Christine Gilmour, Mrs Linda Johnstone, Ms Ann Auld	
2.	<u>Declaration of Interest</u> There were no declarations of interest.	
3.	<u>Matters arising not covered elsewhere on the agenda</u>	
a.	<u>Ratification of minutes of meeting 20th October 2021</u> The minute was accepted as an accurate record and can now be published.	IM
b.	<u>Dapagliflozin in Heart Failure (Non Diabetic)</u> This was deferred until the December meeting.	
c.	<u>Remdesivir – coordination with Clinical Bronze</u> Dr Malekian updated the ADTC on current thinking which is that at this time Clinical Bronze remains the best forum for responding with the appropriate speed and expertise to these issues.	
d.	<u>Creatinine Clearance calculation to determine drug doses</u> Access to calculators remains in place within the MED ED website restricted for NHS Lanarkshire access. The long term plan is being worked on by Mrs Gilmour.	CG
e.	<u>LMWH - Extremes of body weight</u> Mrs Patterson explained that the https://www.sps.nhs.uk/ website remains under review.	

	<p>f. <u>Oxygen Prescribing in Acute Settings</u></p> <p>This is deferred until the December ADTC meeting. It is anticipated that it will be discussed at the Acute Clinical Governance meeting in early Dec.</p> <p>g. <u>Steroid Emergency Cards</u></p> <p>Mrs Gilmour had submitted apologies for todays meeting and this item was deferred until the December meeting.</p> <p>h. <u>Guidance on Production of Guidelines</u></p> <p>There was a useful debate which recognised the value of giving this issue considerable thought for it will guide our practice for some time to come.</p> <p>i. <u>Peripheral Noradrenaline Infusion</u></p> <p>The ADTC will review a pan NHS Lanarkshire guideline when it is submitted.</p> <p>j. <u>Upadacitinib</u></p> <p>This was agreed. Dr Malekian will feedback to the author.</p>	<p>CG</p> <p>MM</p>
	<p>4. <u>SMC</u></p> <p><u>FULL SUBMISSIONS</u></p> <p>Olaparib (Lynparza®) SMC2368 This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN) for comments / clinical protocol.</p> <p>Ibrutinib (Imbruvica®) SMC2387 This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN) for comments / clinical protocol.</p> <p><u>RESUBMISSIONS</u></p> <p>Tafamidis (Vyndaqel®) SMC2426 This was noted.</p> <p>Amikacin (Arikayce®) SMC2432 This was noted and will be referred to both the Antimicrobial Committee and respiratory specialists.</p> <p><u>NON SUBMISSIONS</u></p> <p>Anakinra (Kineret®) SMC2449 This was noted.</p>	

	<p>Nitisinone (Orfadin®) SMC2450 This was noted.</p> <p><u>UPDATE ON THE INTERIM ASSESSMENT APPROACH IN RESPONSE TO COVID-19</u> This is a pragmatic approach to minimise delay in patient access as a result of the COVID-19 pandemic. Following review by the SMC executive, SMC advice for four submissions noted below will be published on the SMC website on Monday 13 December 2021.</p> <p><u>FULL SUBMISSIONS</u></p> <p>Nivolumab (Opdivo®) SMC2394 This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN) for comments / clinical protocol.</p> <p>Tirbanibulin (Klisyri®) SMC2395 This was noted and will be referred to dermatology specialists for comment.</p> <p><u>ABBREVIATED SUBMISSIONS</u></p> <p>Olopatadine hydrochloride / mometasone furoate monohydrate (Ryaltris®) SMC2418 This was noted and will be referred to ENT specialists for comment.</p> <p><u>Deferred Advice</u></p> <p>Buprenorphine (Sixmo®) SMC2372 This was noted and will be referred to specialists in the Addictions Service for comment.</p> <p>PAEDIATRIC LICENCE EXTENSIONS This was noted.</p> <p>UO VALIDATION This was noted.</p>	
5.	<p><u>SMC follow up</u></p> <p>Mrs Maroni talked the committee through the SMC follow up which had been previously circulated. Feedback for 5-aminolevulinic acid (Alacare®) was provided and the corresponding ADTC bulletin will be updated accordingly for this.</p> <p>An SBAR, compiled by paediatric specialists, for midazolam 2mg/ml oral solution (Ozalin®) SMC2392 was discussed by the committee. There was agreement with the rationale to remain with current practice, as outlined in the document. Dr Malekian/Gail Richardson will feedback to the lead author.</p>	<p>KM</p> <p>MM/GR</p>

<p>6. <u>Lanarkshire Formulary</u></p> <p>Following ratification of the clinical protocol at October ADTC, Mrs McGoff proposed the addition of filgotinib to the JAK inhibitors section of Chapter 10. This was approved.</p>		<p>CMcG</p>
<p>7. <u>Clinical Protocols</u></p> <p>1. <u>Ravulizumab</u></p> <p>There remain some abbreviations and Latin terminology, and there was also uncertainty about financial implications which need to be brought to the attention of the Acute Prescribing Management Board. Dr Malekian will feedback to the author.</p> <p>2. <u>Baricitinib</u></p> <p>This was agreed. Dr Malekian will feedback to the author.</p> <p>3. <u>Oral Paracetamol</u></p> <p>The substance of the guideline was agreed. Mrs Patterson will ask Sarah Brady if she will be prepared to be listed as the lead author to facilitate contact at time of review.</p> <p>As part of a wider discussion about key words in titles to facilitate searching it was also suggested that the title be expanded to be Paracetamol for Treatment of Pain. A suggestion of storing guidelines in several places on the APP/website including under relevant BNF Chapter was also put forward.</p> <p>4. <u>Guideline on the use of melatonin for the management of sleep disorders</u></p> <p>Mrs Harris spoke to these guidelines and explained the reason and methodology for the update. It was agreed and can now be published. Mrs Harris agreed to be listed as the lead author for contact at time of review.</p> <p>5. <u>Guselkumab</u></p> <p>The documents were agreed save the following recommendations.</p> <p>Given changes in General Medical services the “GP” Information leaflet contains information which will now be relevant to a broader range of health care professionals so it should be retitled as “Information for Primary Care Healthcare Professionals”. It should also include the indication for treatment.</p>	<p>MM</p> <p>MM</p> <p>KP</p> <p>MM</p>	

	Dr Malekian will feedback to the authors.	
8.	<u>ADTC Bulletin</u> This was noted.	KM
9.	<u>Unlicensed Medicines</u> There was nil to report at this today's meeting.	
10.	<u>Patient Group Directions</u> 1. Chlordiazepoxide An extension until March 2023 was agreed. Mr Lindsay will feedback to Mr Hill 2. Emergency Contraception It was agreed to align this PGD with the recent PGD for Bridging Contraception. A review date of Nov 2023 was agreed and the "aide memoir" will be augmented to prompt consideration of Bridging Contraception. Mr Lindsay will take this forward with Dr McLellan.	GL GL
11.	<u>Medication and Clinical risk in Lanarkshire</u> https://www.gov.uk/drug-safety-update This was noted.	
12.	<u>Regional Cancer Advisory Network</u> There was nil to report at this meeting.	
13.	<u>Patient Safety Alerts</u> There was nil to report at this meeting.	
14.	<u>Lay member related items</u> There was nil to report at this meeting.	
15.	<u>Correspondence</u> 1. <u>ADTCC Correspondence</u> <u>MHRA Early Access to Medicines Scheme: Expiry of nivolumab scientific opinion EAMS number 15105/0015</u> This was noted. 2. <u>ADTCC Forum and Feedback</u>	

